[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"accupuncture\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:accupuncture":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100618859","electro-acupuncture-in-lung-cancer--ealer-study-100618859",false,"NCT07337096","Electro-Acupuncture in Lung cancER : EALER Study","Electro-acupuncture Plus PD-1 Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer: A Randomized Trial","Inclusion Criteria:\n\n1. Pathologically confirmed NSCLC, with AJCC lung cancer TNM stage IV.\n2. Tumor proportion score for PD-L1 \\\u003C 50%.\n3. Lacks targetable gene mutations (including but not limited to EGFR mutations or ALK fusions).\n4. No prior systemic therapy for advanced NSCLC (including chemotherapy, targeted therapy, or immunotherapy). Patients planned to receive first-line (induction) treatment with ICIs plus chemotherapy are eligible. Patients who have received prior neoadjuvant or adjuvant therapy, or definitive chemoradiotherapy, may be enrolled if provided that disease progression occurred more than 6 months after the completion of the last treatment.\n5. ECOG performance status score of 0-2.\n6. Age ≥ 18 years.\n7. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n8. Adequate organ function (hematology: ANC ≥ 1500\u002FmcL, PLT ≥ 100,000\u002FmcL, Hb ≥ 9.0 g\u002FdL or ≥ 5.6 mmol\u002FL; renal function: estimated creatinine clearance ≥ 50 mL\u002Fmin; hepatic function: serum total bilirubin ≤ 1.5 × ULN or total bilirubin \\> 1.5 × ULN with direct bilirubin ≤ ULN, AST and ALT ≤ 2.5 × ULN ≤ 5 × ULN for patients with liver metastases).\n9. Voluntary participation in the study, signed informed consent form, good compliance, and cooperation with follow-up.\n\nExclusion Criteria:\n\n1. Inability to complete baseline assessments.\n2. Pregnant or lactating women, and those with psychiatric, intellectual, or language disorders.\n3. Patients with autoimmune diseases or hematologic disorders requiring long-term use of hormones or immunosuppressants.\n4. Presence of concurrent primary malignant tumors at other sites.\n5. Participation in another investigational drug or device clinical trial within 30 days prior to the planned initiation of study treatment.\n6. Known seropositivity for human immunodeficiency virus (HIV), other congenital or acquired immunodeficiencies, or history of organ or stem cell transplantation (including autologous bone marrow or peripheral blood stem cell transplantation).\n7. Loss of self-care capacity, or any medical, psychological, or ethical condition that, in the investigator's judgment, could interfere with the patient's ability to complete the study.\n8. Active skin infection, ulceration, or lesion at acupuncture point sites that would preclude safe administration of treatment.\n9. Implanted cardiac pacemaker or other active implantable electronic medical device.\n10. Severe needle phobia that would prevent acceptance of needling procedures required by the study protocol.\n11. Receipt of any acupuncture or related needle-based therapy within 6 weeks prior to enrollment.\n12. Active pneumonitis, or radiation pneumonitis requiring treatment with systemic corticosteroids.\n13. Active infection requiring antimicrobial therapy (antibacterial, antifungal, or antiviral agents) according to clinical guidelines at the time of screening. Enrollment may be reconsidered after the infection has been adequately controlled.\n14. Active tuberculosis infection, or any severe or uncontrolled systemic illness, including but not limited to clinically significant neurological conditions (e.g., uncontrolled seizures, dementia), unstable or decompensated respiratory, cardiac, hepatic, or renal disease.","ALL","18 Years",{"count":19,"type":20},424,"ESTIMATED","INTERVENTIONAL",[23],"NA","This multicentre, randomized controlled trial evaluates the effect and safety of acupuncture combing with PD-1 inhibitors plus chemotherapy in NSCLC. Participants will be randomly assigned to undergo either acupuncture or sham acupuncture concurrent with the initial four-six cycles of chemotherapy combined with PD-1 inhibitors.",[26,27,28],"Non Small Cell Lung Cancer","Accupuncture","PD-1 Inhibitors","RECRUITING","2026-06-22",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":33},"2026-01-15",{"date":37,"type":20},"2028-12",{"name":39,"class":40},"Guangzhou University of Traditional Chinese Medicine","OTHER",3,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100637145","comparing-acupuncture-vs-sham-acupuncture-for-the-management-of-hot-flashes-in-prostate-cancer-patients-receiving-hormone-therapy-100637145","NCT07594002","Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy","Inclusion Criteria:\n\n* Patients with history of prostate cancer with currently receiving hormone therapy or had received hormone therapy in the past two years\n* Hormone therapies may include androgen deprivation therapy ( ADT; e.g., leuprolide, degarelix, or relugolix) or androgen signaling inhibitors (e.g., enzalutamide, apalutamide, or darolutamide) or adrenal steroid synthesis inhibitor (e.g., abiraterone acetate).\n* Patients may also receive additional treatments such as chemotherapy, radioligand therapy or target therapy in combination with hormone therapy.\n* Reports hot flashes at least twice per day. Patients may already be taking medications for hot flashes. There is no limit on the number of hot flash medications they can be using.\n* ECOG performance status =3 (see Appendix A).\n* Patients may participate in other therapeutic clinical trials for the treatment of prostate cancer. They will remain eligible as long as they meet the eligible criteria.\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.\n* Patients with a prior or concurrent malignancy are eligible for this trial.\n* Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* Patients can't travel for acupuncture\n* Patients with high bleeding tendency as determined by PI","99 Years",{"count":50,"type":20},40,[23],"This study is evaluating whether acupuncture may help reduce hot flashes in men receiving hormone therapy for prostate cancer. Hot flashes are a common side effect of androgen deprivation therapy (ADT) and may negatively affect sleep, mood, concentration, daily activities, and overall quality of life.\n\nParticipants enrolled in this study will receive acupuncture treatment over a defined treatment period. The study will assess changes in hot flash frequency, severity, and quality of life using patient questionnaires and symptom diaries. Participants will complete a daily hot flash diary during selected 7-day assessment periods and quality-of-life questionnaires during study visits.\n\nThe primary goal of this study is to determine whether acupuncture may improve hot flash symptoms and related quality of life in men undergoing treatment for prostate cancer.",[27,54,55,56],"Prostate Cancer","Hormone Therapy","Hot Flashes",[54,56,58],"Androgen Deprivation Therapy","NOT_YET_RECRUITING","2026-05-21",{"date":62,"type":33},"2026-05-27",{"date":64,"type":20},"2026-06-05",{"date":66,"type":20},"2028-05-31",{"name":68,"class":40},"University of Kentucky",1]